Study of the Efficacy of Autologous Cell Therapy in Dilated Cardiomyopathy

Meruyert Latipbayeva 1 * , Manarbek Askarov 2, Telman Seisembekov 3, Abay Baigenzhin 4, Bulat Kupenov 5, Almas Tolegenuly 6, Dinara Zakarina 1, Aikumis Mansharipova 1, Aizhan Akhayeva 7, Gulzi Kussaiynkhan 1
More Detail
1 Department of Interventional Cardiology №2, National Scientific Medical Research Center JSC, Astana, Kazakhstan
2 Сell technology department, National Scientific Medical Research Center JSC, Astana, Kazakhstan
3 Astana Medical University, Astana, Kazakhstan
4 Chairman of the Board, National Scientific Medical Center, Astana, Kazakhstan
5 Management Director, National Scientific Medical Research Center JSC, Astana, Kazakhstan
6 Heart institute, National Scientific Medical Research Center JSC, Astana, Kazakhstan
7 Center for Cell Technologies, National Scientific Medical Research Center JSC, Astana, Kazakhstan
* Corresponding Author
J CLIN MED KAZ, Volume 22, Issue 4, pp. 37-46. https://doi.org/10.23950/jcmk/16589
OPEN ACCESS 1046 Views 97 Downloads
Download Full Text (PDF)
Author Contributions: Recruitment of patients into the study, M. L., A. M. and D. Z.; patient hospitalization, B. K.; inclusion of patients and collection of research material, M. L.; bone marrow collection, M. A. and A. T.; cell culturing, A. A.; writing – original draft preparation, M. L.; writing – review and editing, T. S. and M. A.; supervision, A. B. All authors have read and agreed to the published version of the manuscript.

Data availability statement: The corresponding author can provide the data supporting the study's conclusions upon request. Due to ethical and privacy constraints, the data are not publicly accessible.

Informed Consent: Written informed consent was obtained from all participants included in the study.

Studies involving human subjects were conducted in accordance with institutional and international ethical standards.

ABSTRACT

Background: Dilated cardiomyopathy (DCM) is one of the main causes of heart failure induction all over the world. In non-clinical trial many authors have demonstrated safety and effectiveness of autologous mesenchymal stem cells (MSCs). However, effectiveness of autologous MSCs in DCM with reduced ejection fraction (HFrEF) (≤40%) has been studied insufficiently.
Objective: To evaluate effectiveness of autologous cell therapy in patients with dilated cardiomyopathy and reduced left ventricular ejection fraction.                                                                                               
Methods: This single center randomized clinical study included 61 patients with DCM, class III-IV of heart failure according to New York Heart Association (NYHA), with HFrEF (≤40%) who made 2 visits every 3 months. Patients included in the study were randomized into two groups: the main group (32 patients) and the control group (29 patients). Patients of the main group received standard optimal medical therapy (OMT) and cell therapy, and patients of the second group received OMT. Data were analyzed using SPSS Statistica 10 and GraphPad Prism 7.
Results: The median patient age in control group was 57.0±12.0 and in the main group was 47.0±10.4 years.  On average ~2/3 of the total number of patients were male in both groups. Disease duration in control group was 4.9 ± 3.1, and in main group was 4.8 ± 2.8. Сomorbidities: type 2 diabetes mellitus (DM), arterial hypertension (AH) and cardiac arrhythmias (CA) did not differ between groups amounting to 17 to 44% of all patients. After 12 months of observation main group showed significant improvements associated with cell therapy: based on the results of laboratory test: statistically significant decrease in the level of eosinophils, normalization of coagulogram parameters, decrease in urea and increase in blood calcium, furthermore, there was a notable increase in anti-inflammatory cytokines CD73+ and IL-4, alongside reduction in pro-inflammatory CD8+ levels and brain natriuretic peptide (NT-proBNP). Echocardiographic (ECHO) data revealed significant increase in LVEF from 26.1 ± 8.4% to 37.6 ± 7.6% (p<0.0001) and reduction in end-systolic volume (ESV) from 146 ± 54   to 113 ± 42  p=0.0496) in the main group, whereas no such changes were observed in the control group.
Conclusion:  Combined therapy, including OMT and cell therapy, resulted in improved left ventricular function, reduced cardiac chamber dimensions (according to echocardiographic data), decreased pro-BNP levels, and improved routine laboratory parameters. However, these findings require confirmation in large-scale, multicenter randomized clinical trial
Keywords: heart failure, dilated cardiomyopathy, cell therapy, mesenchymal stem cells.
Keywords: heart failure, dilated cardiomyopathy, cell therapy, mesenchymal stem cells

CITATION

Latipbayeva M, Askarov M, Seisembekov T, Baigenzhin A, Kupenov B, Tolegenuly A, et al. Study of the Efficacy of Autologous Cell Therapy in Dilated Cardiomyopathy. J CLIN MED KAZ. 2025;22(4):37-46. https://doi.org/10.23950/jcmk/16589

REFERENCES

  • Korotaeva AA, Samoilova EV, Mindzaev DR, Nasonova SN, Zhirov IV, Tereshchenko SN. Proinflammatory cytokines in chronic heart failure: state of the problem. Therapeutic archive. 2021; 93(11): 1389–1394. https://doi.org/10.26442/00403660.2021.11.201170
  • Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de Ferranti S, Després JP, Fullerton HJ, Howard VJ, Huffman MD, Isasi CR, Jiménez MC, Judd SE, Kissela BM, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Magid DJ, McGuire DK, Mohler ER 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Rosamond W, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Woo D, Yeh RW, Turner MB. American Heart Association Statistics Committee; Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2016 Update: A Report From the AHA. Circulation. 2016; 133(4): e38–e360. https://doi.org/10.1161/CIR.0000000000000350.
  • Vaykhanskaya TG, Sivitskaya LN, Kurushko TV, Levdansky OD, Danilenko NG. Dilated cardiomyopathy: reconceptualization of the problem. Russian J. Car. 2019; 24(4): 35–47 http://dx.doi.org/10.15829/1560-4071-2019-4-35-47
  • Reichart D, Magnussen C, Zeller T, Blankenberg S. Dilated cardiomyopathy: from epidemiologic to genetic phenotypes: A translational review of current literature. J Intern Med. 2019; 286(4): 362–372. https://doi.org/10.1111/joim.12944
  • Charron P, Elliott PM, Gimeno JR, Caforio ALP, Kaski JP, Tavazzi L, Tendera M, Maupain C, Laroche C, Rubis P, Jurcut R, Calò L, Heliö TM, Sinagra G, Zdravkovic M, Kavoliuniene A, Felix SB, Grzybowski J, Losi MA, Asselbergs FW, García-Pinilla JM, Salazar-Mendiguchia J, Mizia-Stec K, Maggioni AP. EORP Cardiomyopathy Registry Investigators. The Cardiomyopathy Registry of the EURO bservational Research Programme of the European Society of Cardiology: baseline data and contemporary management of adult patients with cardiomyopathies. Eur Heart J. 2018; 39(20): 1784–1793. https://doi.org/10.1093/eurheartj/ehx819
  • Filippov EV, Yakushin SS. Dilated cardiomyopathy: differential diagnosis, approaches to therapy, surgical treatment. J Cardiology. 2017; (2): 91–97. https://doi.org/10.24411/2309-1908-2017-00030
  • Rossano JW, Dipchand AI, Edwards LB, Goldfarb S, Kucheryavaya AY, Levvey Rn BJ, Lund LH, Meiser B, Yusen RD, Stehlik J. International Society for Heart and Lung Transplantation. The Registry of the International Society for Heart and Lung Transplantation: Nineteenth Pediatric Heart Transplantation Report-2016; Focus Theme: Primary Diagnostic Indications for Transplant. J Heart Lung Transplant. 2016; 35(10): 1185–1195. https://doi.org/10.1016/j.healun.2016.08.018
  • Lund LH, Edwards LB, Dipchand AI, Goldfarb S, Kucheryavaya AY, Levvey BJ, Meiser B, Rossano JW, Yusen RD, Stehlik J. International Society for Heart and Lung Transplantation. The Registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Heart Transplantation Report-2016; Focus Theme: Primary Diagnostic Indications for Transplant. J Heart Lung Transplant. 2016; 35(10): 1158–1169. https://doi.org/10.1016/j.healun.2016.08.017
  • McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Skibelund AK; ESC Scientific Document Group. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023; 44(37): 3627–3639. https://doi.org/10.1093/eurheartj/ehad613
  • Maddox TM, Januzzi JL Jr, Allen LA, Breathett K, Butler J, Davis LL, Fonarow GC, Ibrahim NE, Lindenfeld J, Masoudi FA, Motiwala SR, Oliveros E, Patterson JH, Walsh MN, Wasserman A, Yancy CW, Youmans QR. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021; 77(6): 772–810. https://doi.org/10.1016/j.jacc.2020.11.022
  • Domae K, Miyagawa S, Yoshikawa Y, Fukushima S, Hata H, Saito S, Kainuma S, Kashiyama N, Iseoka H, Ito E, Harada A, Takeda M, Sakata Y, Toda K, Pak K, Yamada T, Sawa Y. Clinical Outcomes of Autologous Stem Cell-Patch Implantation for Patients With Heart Failure With Nonischemic Dilated Cardiomyopathy. J Am Heart Assoc. 2021; 10(13): e008649. https://doi.org/10.1161/JAHA.117.008649
  • Markus Y, Ranish Deedar Ali Khawaja, Daniel Vargas, Heart Transplantation: Indications, Surgical Techniques, and Complications. Radiologic Clinics of North America. 2023; 61(5): 847–859. https://doi.org/10.1016/j.rcl.2023.04.011
  • Zafranskaya MM, Nizhegorodova DB. “Mesenchymal stem cells as a strategy for treating multiple sclerosis: current problems and prospects”. Medical Immunology. 2017; 19 (6): 683–704. https://doi.org/10.15789/1563-0625-2017-6-683-704
  • Ding DC, Shyu WC, Lin SZ, Li H. The role of endothelial progenitor cells in ischemic cerebral and heart diseases. Cell Transplant. 2007; 16(3): 273–284. https://doi.org/10.3727/000000007783464777
  • Lykov AP. Mesenchymal stem cells: properties and clinical application. Sib Scientific Med J. 2023; 43(2): 40–53. https://doi.org/10.18699/SSMJ20230204
  • Zafranskaya MM, Nizhegorodova DB. Mesenchymal stem cells as a strategy for the treatment of multiple sclerosis: Current problems and prospects. Medical immunology. 2017; 19(6): 683–704. https://doi.org/10.15789/1563-0625-2017-6-683-704
  • Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop Dj, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006; 8(4): 315–317. https://doi.org/10.1080/14653240600855905
  • Williams AR, Hare JM. Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Research. 2011; 109(8): 923–940. https://doi.org/10.1161/circresaha.111.243147
  • Onishchenko NA, Nikolskaya AO, Gonikova ZZ, Kirsanova LA, Shagidulin MYu. Regenerative and hepatospecific activity Of total RNA from xenogenic Bone Marrow cells. Rus j of transp & artificial org. 2021; 13: 43–48. https://doi.org/10.15825/1995-1191-2021-1
  • Tkach M, Théry C. Communication by Extracellular Vesicles: Where We Are and Where We Need to Go. Cell. 2016; 164(6): 1226–1232. https://doi.org/10.1016/j.cell.2016.01.043
  • Abels ER, Breakefield XO. Introduction to Extracellular Vesicles: Biogene sis, RNA Cargo Selection, Content, Release, and Uptake. Cellular and Molecular Neurobiology. 2016; 36(3): 301–312. https://doi.org/10.1007/s10571-016-0366-z
  • Zhang B, Tian X, Hao J, Xu G, Zhang W. Mesenchymal Stem Cell-De rived Extracellular Vesicles in Tissue Regeneration. Cell Transplantation. 2020; 29: 963689720908500. https://doi.org/10.1177/0963689720908500
  • Terriaca S, Fiorelli E, Scioli MG, Fabbri G, Storti G, Cervelli V, Orlandi A. Endothelial Progenitor Cell-Derived Extracellular Vesicles: Potential Therapeutic Application in Tissue Repair and Regeneration. Int J Mol Sci. 2021; 22(12): 6375. https://doi.org/10.3390/ijms22126375
  • Wiklander OPB, Brennan MÁ, Lötvall J, Breakefield XO, El Andaloussi S. Advances in therapeutic applications of extracellular vesicles. Sci Transl Med. 2019; 11(492): 8521. https://doi.org/10.1126/scitranslmed.aav8521
  • Kelkar AA, Butler J, Schelbert EB, Greene SJ, Quyyumi AA, Bonow RO, Cohen I, Gheorghiade M, Lipinski MJ, Sun W, Luger D, Epstein SE. Mechanisms Contributing to the Progression of Ischemic and Nonischemic Dilated Cardiomyopathy: Possible Modulating Effects of Paracrine Activities of Stem Cells. J Am Coll Cardiol. 2015; 66(18): 2038–2047. https://doi.org/10.1016/j.jacc.2015.09.010
  • Butler J, Epstein SE, Greene SJ, Quyyumi AA, Sikora S, Kim RJ, Anderson AS, Wilcox JE, Tankovich NI, Lipinski MJ, Ko YA, Margulies KB, Cole RT, Skopicki HA, Gheorghiade M. Intravenous Allogeneic Mesenchymal Stem Cells for Nonischemic Cardiomyopathy: Safety and Efficacy Results of a Phase II-A Randomized Trial. Circ Res. 2017; 120(2): 332–340. https://doi.org/10.1161/CIRCRESAHA.116.309717
  • Terashvili M, Bosnjak ZJ. Stem Cell Therapies in Cardiovascular Disease. J Cardiothoracic Vasc An. 2019; 33(1): 209–222. https://doi.org/10.1053/j.jvca.2018.04.048
  • Florea V, Rieger AC, DiFede DL, El-Khorazaty J, Natsumeda M, Banerjee MN, Tompkins BA, Khan A, Schulman IH, Landin AM, Mushtaq M, Golpanian S, Lowery MH, Byrnes JJ, Hendel RC, Cohen MG, Valasaki K, Pujol MV, Ghersin E, Miki R, Delgado C, Abuzeid F, Vidro-Casiano M, Saltzman RG, DaFonseca D, Caceres LV, Ramdas KN, Mendizabal A, Heldman AW, Mitrani RD, Hare JM. Dose Comparison Study of Allogeneic Mesenchymal Stem Cells in Patients With Ischemic Cardiomyopathy (The TRIDENT Study). Circ Res. 2017; 121(11): 1279–1290. https://doi.org/10.1161/CIRCRESAHA.117.311827
  • Dergilev KV, Vasilets ID, Tsokolaeva ZI, Zubkova ES, Parfenova EV. Perspectives of cell therapy for myocardial infarction and heart failure based on cardiosphere cells. Ter Arkh. 2020; 92(4): 111–120. https://doi.org/10.26442/00403660.2020.04.000634
  • Fisher SA, Doree C, Mathur A, Taggart DP, Martin-Rendon E. Stem cell therapy for chronic ischaemic heart disease and congestive heart failure. Cochrane Database of Systematic Reviews. 2016; 12(12): CD007888. https://doi.org/10.1002/14651858.CD007888.pub3
  • Dzholdasbekova A, Fedotovskikh G, Askarov M, Komsabakova B, Baigenzhina A, Kairatova A, Abylkassymova G. Systemic administration of autologous mononuclear precultured bone marrow stem cells in heart failure. J Clin Med Kaz 2015; 3(37): 14–18. https://www.clinmedkaz.org/download/systemic-administration-of-autologous-mononuclear-precultured-bone-marrow-stem-cells-in-heart-8777.pdf
  • Harjola V, Mullens W, Banaszewski M, Bauersachs J, Brunner-La Rocca H P, Chioncel O, Collins S P, Doehner W, Filippotas G S, Flammer A J, Legrand M, Masip J, Mueller C, Papp Z, Parissis J, Platz E. Organ Dysfunction, injury and failure in acute HF: from pathophysiology to diagnosis and management. A review on behalf of the AHF Committee of the HFA of the ESC. Europ J. HF. 2017; 19: 821–836. https://doi.org/10.1002/ejhf.872
  • Mojsilovic-Petrovic J, Callaghan D, Cui H, Dean C, Stanimirovic DB, Zhang W. Hypoxia-inducible factor-1 (HIF-1) is involved in the regulation of hypoxia-stimulated expression of monocyte chemoattractant protein-1 (MCP-1/CCL2) and MCP-5 (Ccl12) in astrocytes. J Neuroinflammation. 2007; 4: 12. https://doi.org/10.1186/1742-2094-4-12
  • Van Tassell BW, Toldo S, Mezzaroma E, Abbate A. Targeting interleukin-1 in heart disease. Circulation. 2013; 128(17): 1910–1923. https://doi.org/10.1161/CIRCULATIONAHA.113.003199
  • Askarov M.B., Baigenzhin A.K. Restorative and replacement therapy with bone marrow mesenchymal stem cells of lost functions of organs and systems in chronic pathology Print-Sprint Publishing House; Astana. 2024. 113 p.
  • Arslan U, Brescia M, Meraviglia V, Nahon DM, van Helden RWJ, Stein JM, van den Hil FE, van Meer BJ, Vila Cuenca M, Mummery CL, Orlova VV. Vascularized hiPSC-derived 3D cardiac microtissue on chip. Stem Cell Reports. 2023; 18(7): 1394–1404. https://doi.org/10.1016/j.stemcr.2023.06.001
  • Deng T, Jovanovic VM, Tristan CA, Weber C, Chu PH, Inman J, Ryu S, Jethmalani Y, Ferreira de Sousa J, Ormanoglu P, Twumasi P, Sen C, Shim J, Jayakar S, Bear Zhang HX, Jo S, Yu W, Voss TC, Simeonov A, Bean BP, Woolf CJ, Singeç I. Scalable generation of sensory neurons from human pluripotent stem cells. Stem Cell Reports. 2023; 18(4): 1030–1047. https://doi.org/10.1016/j.stemcr.2023.03.006